兴奋剂药物的使用与生长激素治疗反应：一项全国儿童生长研究（NCGS）数据库分析

Stimulant medication use and response to growth hormone therapy: an NCGS database analysis.

作者信息

Frindik J Paul, Morales Alba, Fowlkes John, Kemp Stephen, Thrailkill Kathryn, Lippe Barbara, Dana Ken

机构信息

University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

出版信息

Horm Res. 2009;72(3):160-6. doi: 10.1159/000232491. Epub 2009 Sep 1.

DOI:10.1159/000232491

PMID:19729947

Abstract

BACKGROUND/AIMS: Determine (1) frequency of attention-deficit hyperactivity disorder (ADHD) treatment and (2) growth responses in growth hormone (GH)-treated children who are receiving ADHD medication versus GH alone.

METHODS

Prepubertal children with idiopathic short stature (ISS) or GH deficiency (IGHD) enrolled in Genentech's National Cooperative Growth Study. ADHD treatment was determined by documentation of psycho-stimulant medication use at enrollment.

RESULTS

ADHD medication use increased from 0.8% (7/850) in 1985 to 5.8% (752/12,113) in 2005. First-year GH treatment response for ADHD + IGHD versus IGHD: 8.5 +/- 2.0 vs. 9.4 +/- 2.6 cm/year, but when adjusted for age, sex, and enrollment body mass index, the difference is clinically insignificant (-0.4 cm/year). First-year growth was similar in all ISS: 8.1 +/- 1.9 versus 8.6 +/- 2.1 cm/year (ADHD + ISS vs. ISS, an adjusted -0.2-cm/year difference).

CONCLUSION

Increasing numbers of GH-treated children are taking ADHD medications and their growth responses during the first year of GH therapy are similar to those not taking ADHD medications.

摘要

背景/目的：确定（1）注意力缺陷多动障碍（ADHD）的治疗频率，以及（2）接受ADHD药物治疗的生长激素（GH）治疗儿童与仅接受GH治疗的儿童的生长反应。

方法

参加基因泰克全国合作生长研究的青春期前特发性矮小（ISS）或生长激素缺乏（IGHD）儿童。ADHD治疗通过入组时精神兴奋剂药物使用记录来确定。

结果

ADHD药物使用从1985年的0.8%（7/850）增加到2005年的5.8%（752/12,113）。ADHD + IGHD组与IGHD组的第一年GH治疗反应：8.5±2.0 vs. 9.4±2.6厘米/年，但在根据年龄、性别和入组时体重指数进行调整后，差异在临床上无显著意义（-0.4厘米/年）。所有ISS组的第一年生长情况相似：8.1±1.9 vs. 8.6±2.1厘米/年（ADHD + ISS组与ISS组，调整后差异为-0.2厘米/年）。